Patents by Inventor Itamar YADID

Itamar YADID has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS COMPRISING LTB AND PATHOGENIC ANTIGENS, AND USE THEREOF
    Publication number: 20230190923
    Abstract: The present invention is directed to compositions of immunogenic polypeptides including a heat labile toxin subunit B (LTB) polypeptide and a plurality of viral polypeptides. Further provided are compositions and methods of using same, such as for vaccinating a subject in need thereof.
    Type: Application
    Filed: February 25, 2021
    Publication date: June 22, 2023
    Applicant: MIGAL GALILEE RESEARCH INSTITUTE LTD.
    Inventors: Jacob PITCOVSKI, Ehud SHAHAR, Itai BLOCH, Itamar YADID, Ran BEN ADIVA, Chen KATZ, Nady GRUZDEV
  • Endoinulinases
    Patent number: 11655463
    Abstract: A modified endoinulinase is provided, comprising modified wild-type T. purpuregenus endoinulinase, or a functional fragment thereof, in which an amino acid residue at each one of one or more positions corresponding to 128, 316, 344, 350 or 504 of wild-type T. purpuregenus endoinulinase is substituted, wherein: (i) a tyrosine residue corresponding to Y128 is substituted with H, K or R; a glutamate residue corresponding to E344 is substituted with K, H or R; and a threonine residue corresponding to T504 is substituted with M, S or Y; and optionally an alanine residue corresponding to A316 is substituted with T, S, C or M; (ii) a tyrosine residue corresponding to Y128 is substituted with H, K or R; a glutamate residue corresponding to E344 is substituted with K, H or R; a threonine residue corresponding to T504 is substituted with M, S or Y; and a glutamine residue corresponding to Q350 is substituted with L, G, A, V or I; or (iii) a tyrosine residue corresponding to Y128 is substituted with H, K or R.
    Type: Grant
    Filed: January 31, 2021
    Date of Patent: May 23, 2023
    Assignee: MIGAL GALILEE RESEARCH INSTITUTE LTD.
    Inventors: Itamar Yadid, Rami Cohen, Livnat Afriat-Jurnou
  • IMPROVED ENDOINULINASES
    Publication number: 20210155914
    Abstract: A modified endoinulinase is provided, comprising modified wild-type T. purpuregenus endoinulinase, or a functional fragment thereof, in which an amino acid residue at each one of one or more positions corresponding to 128, 316, 344, 350 or 504 of wild-type T. purpuregenus endoinulinase is substituted, wherein: (i) a tyrosine residue corresponding to Y128 is substituted with H, K or R; a glutamate residue corresponding to E344 is substituted with K, H or R; and a threonine residue corresponding to T504 is substituted with M, S or Y; and optionally an alanine residue corresponding to A316 is substituted with T, S, C or M; (ii) a tyrosine residue corresponding to Y128 is substituted with H, K or R; a glutamate residue corresponding to E344 is substituted with K, H or R; a threonine residue corresponding to T504 is substituted with M, S or Y; and a glutamine residue corresponding to Q350 is substituted with L, G, A, V or I; or (iii) a tyrosine residue corresponding to Y128 is substituted with H, K or R.
    Type: Application
    Filed: January 31, 2021
    Publication date: May 27, 2021
    Inventors: Itamar YADID, Rami COHEN, Livnat AFRIAT-JURNOU
  • Endoinulinases
    Patent number: 10941386
    Abstract: A modified endoinulinase is provided, comprising modified wild-type T. purpuregenus endoinulinase, or a functional fragment thereof, in which an amino acid residue at each one of one or more positions corresponding to 128, 316, 344, 350 or 504 of wild-type T. purpuregenus endoinulinase is substituted, wherein: (i) a tyrosine residue corresponding to Y128 is substituted with H, K or R; a glutamate residue corresponding to E344 is substituted with K, H or R; and a threonine residue corresponding to T504 is substituted with M, S or Y; and optionally an alanine residue corresponding to A316 is substituted with T, S, C or M; (ii) a tyrosine residue corresponding to Y128 is substituted with H, K or R; a glutamate residue corresponding to E344 is substituted with K, H or R; a threonine residue corresponding to T504 is substituted with M, S or Y; and a glutamine residue corresponding to Q350 is substituted with L, G, A, V or I; or (iii) a tyrosine residue corresponding to Y128 is substituted with H, K or R.
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: March 9, 2021
    Assignee: MIGAL GALILEE RESEARCH INSTITUTE LTD.
    Inventors: Itamar Yadid, Rami Cohen, Livnat Afriat-Jurnou
  • IMPROVED ENDOINULINASES
    Publication number: 20200270592
    Abstract: A modified endoinulinase is provided, comprising modified wild-type T. purpuregenus endoinulinase, or a functional fragment thereof, in which an amino acid residue at each one of one or more positions corresponding to 128, 316, 344, 350 or 504 of wild-type T. purpuregenus endoinulinase is substituted, wherein: (i) a tyrosine residue corresponding to Y128 is substituted with H, K or R; a glutamate residue corresponding to E344 is substituted with K, H or R; and a threonine residue corresponding to T504 is substituted with M, S or Y; and optionally an alanine residue corresponding to A316 is substituted with T, S, C or M; (ii) a tyrosine residue corresponding to Y128 is substituted with H, K or R; a glutamate residue corresponding to E344 is substituted with K, H or R; a threonine residue corresponding to T504 is substituted with M, S or Y; and a glutamine residue corresponding to Q350 is substituted with L, G, A, V or I; or (iii) a tyrosine residue corresponding to Y128 is substituted with H, K or R.
    Type: Application
    Filed: August 7, 2018
    Publication date: August 27, 2020
    Inventors: Itamar YADID, Rami COHEN, Livnat AFRIAT-JURNOU